These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 6848162)

  • 1. Storage conditions of live measles, mumps and rubella virus vaccines in Montreal.
    Steinmetz N; Furesz J; Reinhold C; Yarosh W
    Can Med Assoc J; 1983 Jan; 128(2):162-3. PubMed ID: 6848162
    [No Abstract]   [Full Text] [Related]  

  • 2. A European collaborative study to assess the proficiency of laboratory estimates of potency of live measles, mumps and rubella tri-valent vaccines.
    Forsey T; Heath AB; Minor PD
    Biologicals; 1993 Sep; 21(3):239-49. PubMed ID: 8117437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination.
    Lerman SJ; Bollinger M; Brunken JM
    Pediatrics; 1981 Jul; 68(1):18-22. PubMed ID: 7017582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendation of the Public Health Service Advisory Committee on Immunization Practices. Combination live virus vaccines: measles and rubella measles, mumps and rubella.
    J Kans Med Soc; 1971 Oct; 72(10):428 passim. PubMed ID: 5109988
    [No Abstract]   [Full Text] [Related]  

  • 5. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients.
    King SM; Saunders EF; Petric M; Gold R
    Bone Marrow Transplant; 1996 Apr; 17(4):633-6. PubMed ID: 8722367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K; Nicoara C; Germann D; Matter L
    Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Administration of measles-mumps-rubella vaccination with other childhood schedule vaccines.
    Heath TC; Burgess MA; O'Brien ED
    Commun Dis Intell; 1998 Aug; 22(8):159. PubMed ID: 9735551
    [No Abstract]   [Full Text] [Related]  

  • 8. [Experience with preventive measles, mumps and rubella vaccination in unified Germany].
    Gerike E; Tischer A
    Gesundheitswesen; 1993 Jan; 55(1):38-9. PubMed ID: 8435543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlates of lymphoproliferative responses to measles, mumps, and rubella (MMR) virus vaccines following MMR-II vaccination in healthy children.
    Dhiman N; Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA
    Clin Immunol; 2005 May; 115(2):154-61. PubMed ID: 15885638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical safety issues of measles, mumps and rubella vaccines.
    Afzal MA; Minor PD; Schild GC
    Bull World Health Organ; 2000; 78(2):199-204. PubMed ID: 10743285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the safety and immunogenicity of a refrigerator-stable versus a frozen formulation of ProQuad (measles, mumps, rubella, and varicella virus vaccine live).
    Bernstein HH; Eves K; Campbell K; Black SB; Twiggs JD; Reisinger KS; Conti RM; Flodmark CE; Rombo L; Klopfer S; Schödel F; Hartzel J; Kuter BJ;
    Pediatrics; 2007 Jun; 119(6):e1299-305. PubMed ID: 17502347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The measles-mumps-rubella vaccination program in Finland.
    Lerman SJ
    N Engl J Med; 1995 Apr; 332(16):1103. PubMed ID: 7898541
    [No Abstract]   [Full Text] [Related]  

  • 13. [Certain problems with limits of immunity against measles, mumps and rubella].
    Magdzik W
    Przegl Epidemiol; 1993; 47(1-2):47-53. PubMed ID: 8351387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moving the second dose of measles-mumps-rubella vaccine to school entry: implications for control of rubella.
    Heath TC; Burgess MA; Forrest JM
    Commun Dis Intell; 1998 Aug; 22(8):157-8. PubMed ID: 9735550
    [No Abstract]   [Full Text] [Related]  

  • 15. Epidemiology of mumps in Quebec, 1970-1995.
    De Serres G; Boulianne N; Bussières N; Pouliot B; Marin-Lira A
    Can Commun Dis Rep; 1997 Jan; 23(2):9-13. PubMed ID: 9136223
    [No Abstract]   [Full Text] [Related]  

  • 16. ACIP issues recommendations to eliminate measles, rubella and congenital rubella syndrome and to control mumps.
    Rose VL
    Am Fam Physician; 1998 Nov; 58(7):1682, 1685-6. PubMed ID: 9824963
    [No Abstract]   [Full Text] [Related]  

  • 17. [Vaccination rate for triple measles-rubella-mumps vaccine in Empoli Val d'Elsa area health district U.S.L. 11, Tuscany Region].
    Salvadori P
    Ann Ig; 1998; 10(1):19-24. PubMed ID: 9616974
    [No Abstract]   [Full Text] [Related]  

  • 18. Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination. Should we be concerned?
    Watada B; Kennedy K; Chan D; Church B; Patriquin M; Shariff F; Evans MF
    Can Fam Physician; 1998 Jan; 44():53-5. PubMed ID: 9481462
    [No Abstract]   [Full Text] [Related]  

  • 19. Measles, mumps, and rubella: prevention.
    Booy R; Sengupta N; Bedford H; Elliman D
    Clin Evid; 2006 Jun; (15):448-68. PubMed ID: 16973018
    [No Abstract]   [Full Text] [Related]  

  • 20. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
    Stohrer-Draxl P; Amstad H; Grize L; Gassner M; Takken-Sahli K; Bourquin C; Braun-Fahrländer C
    Praxis (Bern 1994); 1999 Jun; 88(24):1069-77. PubMed ID: 10420798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.